Cochlear Ltd. received approval from the U.S. Food and Drug Administration for first remote programming option for its hearing implant devices, the Nucleus Cochlear Implant System.
The regulator approved remote feature to allow follow-up programming sessions for the implant through a telemedicine platform.
Cochlear said supplemental labeling, including instructions for use, will be added in 2018 to Custom Sound, its fitting software, to guide clinicians in remote programming.
